WALTHAM, Mass.--(Business Wire)--
NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the
Company`s Chief Executive Officer, will be presenting at the following
conferences:
* The BIO Investor Forum on Wednesday, October 28th at 2:30 pm Pacific Time in
the Sea Cliff room at the Palace Hotel in San Francisco.
* BIO-Europe on Tuesday, November 3rd at 4:00 pm Central European Time in room
Schubert 2 at the Messe Wien Exhibition & Congress Center in Vienna, Austria.
These presentations will provide an overview of NeurAxon and its portfolio of
internally generated, novel, proprietary pain therapeutics including its lead
candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT
agonist which is currently in Phase 2 development for the treatment of acute
migraine.
* Additionally, NeurAxon is pleased to announce that John S. Andrews, Ph.D., the
Company`s President and Head of R&D, has been invited to participate in the
Spotlight Track session "US Healthcare Reform: The International Impact on
Innovation and the Business of Biotech" at BIO-Europe in Vienna, Austria on
Monday, November 2nd at 4:00 pm. The 60-minute panel discussion will cover how
U.S. health care reform may affect innovation and specifically business
development opportunities.
About NeurAxon, Inc.
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain
therapeutics focused on its first-in-class selective inhibitors of neuronal
nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central
nervous system neuronal sensitization.
MacDougall Biomedical Communications
Chris Erdman, 508-647-0209 x14
Copyright Business Wire 2009
